Ziel
HIV/AIDS, Tuberculosis (TB) and Malaria alone account for more than six million deaths worldwide every year. Despite substantial efforts made in recent years, Poverty Related Diseases are still spreading. New therapeutic interventions are therefore urgently required to combat Poverty Related Diseases. The existence of a well-developed HIV/TB/Malaria infrastructure presents a prime opportunity to address other sexually transmitted diseases such as viral hepatitis efficiently and effectively. The overall goal of the EURIPRED is to coordinate and integrate international resources into a single specialised infrastructure to support European HIV, TB, Malaria and Hepatitis B virus and Hepatitis C virus studies from early drug, vaccine and microbicide discovery to clinical trials. This will be achieved by creating partnerships between European scientists and international research teams from disease endemic countries and strong collaborations between industry and public sector research. Although vaccines, drugs and microbicide research is being conducted in the European Union (EU) there is no single European infrastructure that brings international resources and facilities together to develop cost-effective products for the European market. To underpin this need, EURIPRED will integrate worldwide resources to allow European access to shared reagents. This integrated approach will strengthen international cooperation, increase research capacity in EU and developing countries and significantly contribute to the European Research Area (ERA). By minimising fragmentation and duplication of research efforts and pooling fragmented resources EURIPRED can improve European research efficiency and effectiveness. EURIPRED will be built upon the highly successful model of the Centre for AIDS Reagents (CFAR), a twenty-three year old reagent initiative based at the National Institute of Biological Standards and Control (NIBSC), a centre of the Medical Healthcare Products Regulatory Authority Agency (MHRA) and will comprise of a world-class team of experts and repositories with expertise in vaccine, microbicide and drug development for a range of infectious diseases. By engaging international scientific communities, EURIPRED can play a leading role in driving research forward in Europe and beyond.
Wissenschaftliches Gebiet
- medical and health sciencesbasic medicinepharmacology and pharmacydrug discovery
- medical and health scienceshealth sciencesinfectious diseasesmalaria
- medical and health scienceshealth sciencesinfectious diseasesRNA virusesHIV
- medical and health sciencesclinical medicinepneumologytuberculosis
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsvaccines
Aufforderung zur Vorschlagseinreichung
FP7-INFRASTRUCTURES-2012-1
Andere Projekte für diesen Aufruf anzeigen
Finanzierungsplan
CP-CSA-Infra - Combination of CP and CSAKoordinator
SW1W 9SZ London
Vereinigtes Königreich
Auf der Karte ansehen
Beteiligte (19)
Beteiligung beendet
123098 Moscow
Auf der Karte ansehen
WC2R 2LS London
Auf der Karte ansehen
102206 BEIJING
Auf der Karte ansehen
123098 MOSCOW
Auf der Karte ansehen
28029 Madrid
Auf der Karte ansehen
00200 Nairobi
Auf der Karte ansehen
12489 BERLIN
Auf der Karte ansehen
3400 Klosterneuburg
Auf der Karte ansehen
2333 ZA Leiden
Auf der Karte ansehen
50411 TARTU
Auf der Karte ansehen
8219 PK LELYSTAD
Auf der Karte ansehen
1015 LAUSANNE
Auf der Karte ansehen
38126 Braunschweig
Auf der Karte ansehen
OX1 2JD Oxford
Auf der Karte ansehen
WC1E 7HT London
Auf der Karte ansehen
2593 CE DEN HAAG
Auf der Karte ansehen
Beteiligung beendet
109542 MOSKVA
Auf der Karte ansehen
1081 HZ Amsterdam
Auf der Karte ansehen
107113 MOSCOW
Auf der Karte ansehen